Mosby's 2014 Nursing Drug Reference (393 page)

BOOK: Mosby's 2014 Nursing Drug Reference
8.47Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ticagrelor

Brilinta

Func. class.:
Platelet inhibitor

Chem. class.:
ADP receptor antagonist

ACTION:

Reversibly bind to the platelet receptor, preventing platelet activation

USES:

Arterial thromboembolism prophylaxis in acute coronary syndrome (ACS) (unstable angina, acute MI), including in patients undergoing percutaneous coronary intervention (PCI)

CONTRAINDICATIONS:

Hypersensitivity, severe hepatic disease

 

Black Box Warning:

Bleeding, intracranial bleeding

Precautions:
Pregnancy (category C), breastfeeding, infants, neonates, children, GI bleeding, hepatic disease, abrupt discontinuation

 

Black Box Warning:

Coronary artery bypass graft surgery (CABG), surgery

DOSAGE AND ROUTES
Calculator

• Adult:
PO
loading dose 180 mg with aspirin (usually 325 mg PO); then, give 90 mg bid with aspirin 75-100 mg/day, do not give maintenance doses of aspirin >100 mg/day

Available forms:
Tab 90 mg

Administer:

• 
May be taken without regard to food

• 
Discontinue 5-7 days before surgery

• 
May be crushed (90 mg tab) and mixed with purified water, 100 mg (PO) or 50 ml (NG)

SIDE EFFECTS

CNS:
Headache, dizziness, fatigue

CV:
Hypertension, hypotension, chest pain, atrial fibrillation, bradyarrhythmias, syncope, ventricular pauses

GI:
Nausea, diarrhea

HEMA:
Serious, fatal bleeding

MISC:
Back pain, hyperuricemia, gynecomastia

RESP:
Dyspnea, cough

PHARMACOKINETICS

Absolute bioavailability 36%, protein binding (>99%), metabolism by CYP3A4, weak P-glycoprotein substrates and inhibitors, elimination for product and metabolite are hepatic and biliary, 84% excreted in feces, 26% in urine, half-life is 7 hr for ticagrelor, 9 hr for metabolite, maximum inhibition of platelet aggregation (IPA) effect 2 hr, maintained ≥8 hr, peak 1.5 hr product, 2.5 hr metabolite

INTERACTIONS

Increase:
bleeding risk—CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, lopinavir, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, delavirdine, isoniazid, dalfopristin, quinupristin, tipranavir

Decrease:
ticagrelor action—CYP3A4 inducers (rifampin, dexamethasone, phenytoin, carBAMazepine, PHENobarbital)

Increase:
effect of—simvastatin lovastatin

Increase:
bleeding risk—NSAIDs, anticoagulants, platelet inhibitors

Increase or decrease:
digoxin

Drug/Lab Test

Increase:
serum creatinine

NURSING CONSIDERATIONS
Assess:

• 
Thromboembolism:
Monitor CBC with differential with platelet count baseline and periodically during treatment

 

Black Box Warning:

Bleeding:
Assess for bleeding that may occur when aspirin is combined with this product, some bleeding can be fatal

• 
Abrupt discontinuation:
Do not discontinue abruptly, may increase risk for MI, stent thrombosis, death

Perform/provide:

• 
Storage at room temperature, in original container in dry place

Evaluate:

• 
Prevention of thromboembolism

Teach patient/family:

• 
To take only as prescribed, not to skip or double doses; if a dose is missed, to take next dose at scheduled time

 

Black Box Warning:

To notify prescriber of chills, fever, bruising, bleeding

• 
Not to use any prescription, OTC products, herbs without approval of prescriber; products with aspirin, NSAIDs may cause bleeding

• 
To notify all health care providers of product use

• 
That product can be taken without regard to meals

• 
That it may take longer for bleeding to stop

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ticarcillin/clavulanate (Rx)

Timentin

Func. class.:
Broad-spectrum antiinfective

Chem. class.:
Extended-spectrum penicillin, β-lactamase inhibitor

ACTION:

Interferes with cell-wall replication of susceptible organisms; osmotically unstable cell wall swells, bursts from osmotic pressure; clavulanate inhibits β-lactamase and protects against enzymatic degradation of ticarcillin

USES:

Respiratory, soft-tissue, and urinary tract infections; bacterial septicemia; effective for gram-positive cocci
(Staphylococcus aureus, Streptococcus faecalis, Streptococcus pneumoniae)
, gram-negative cocci
(Neisseria gonorrhoeae)
, gram-positive bacilli
(Clostridium perfringens, Clostridium tetani)
, gram-negative bacilli
(Bacteroides, Fusobacterium nucleatum, Escherichia coli, Proteus mirabilis, Salmonella, Morganella morganii, Proteus rettgeri, Enterobacter, Pseudomonas aeruginosa, Serratia);
and
Peptococcus, Peptostreptococcus
, and
Eubacterium

CONTRAINDICATIONS:

Neonates, hypersensitivity to penicillins

Precautions:
Pregnancy (B), hypersensitivity to cephalosporins, renal disease

DOSAGE AND ROUTES
Calculator
Systemic/urinary tract infections, moderate/severe infections

• Adult ≥60 kg:
IV INF
3.1 g q4-6hr

• Adult <60 kg:
IV INF
200-300 mg/kg/day q4-6hr

• Child >60 kg:
IV INF
3.1 g q4-6hr

• Child <60 kg:
IV INF
300 mg/kg/day q4hr

• Full-term neonates/infants <3 mo (unlabeled):
IV
50 mg/kg q4hr for severe infections;
IV
50 mg/kg q6hr for mild to moderate infections

Mild to moderate infections

• Child ≥60 kg:
IV INF
3.1 g q6hr

• Child <60 kg:
IV INF
200 mg/kg/day q6hr

Renal dose

• Adult:
IV INF
loading dose 3.1 g; CCr 60 ml/min, 3.1 g q4hr; CCr 30-60 ml/min, 2 g q4hr; CCr 10-30 ml/min, 2 g q8hr; CCr <10 ml/min, 2 g q12hr; CCr <10 ml/min with hepatic dysfunction, 2 g q24hr

Available forms:
Inj 3 g ticarcillin, 0.1 g clavulanate; IV inf 3 g ticarcillin, 0.1 g clavulanate; powder for inj 3 g ticarcillin, 0.1 g clavulanate

Administer:

• 
Product after C&S, give ≥q1hr before bactericidal anti-infectives, change IV site q48hr

Intermittent IV INF route

• 
After diluting ≤3.1 g/13 ml of sterile water or NaCl (200 mg/ml), shake; may further dilute in ≥50-100 ml NS, D
5
W, or LR sol and run over 1/2 hr

Y-site compatibilities:
Allopurinol, amifostine, amikacin, anidulafungin, atropine, aztreonam, bivalirudin, bumetanide, ceFAZolin, cefepime, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, clindamycin, cyclophosphamide, cycloSPORINE, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, enalaprilat, EPINEPHrine, esmolol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, imipenem/cilastatin, insulin, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, melphalan, meperidine, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pantoprazole, PEMEtrexed, penicillin G potassium, perphenazine, phenylephrine, procainamide, propofol, propranolol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, tirofiban, tobramycin, vasopressin, verapamil, vinorelbine, voriconazole

SIDE EFFECTS

CNS:
Anxiety,
seizures,
confusion, drowsiness

GI:
Nausea, vomiting, diarrhea;
increased AST, ALT; abdominal pain, glossitis, colitis,
pseudomembranous colitis, hepatotoxicity

HEMA:
Anemia, increased bleeding time,
bone marrow depression, granulocytopenia

INTEG:
Rash, urticaria,
toxic epidermal necrolysis,
pain at injection site

META:
Hypokalemia, hypernatremia

SYST:
Anaphylaxis, Stevens-Johnson syndrome,
overgrowth of organisms

PHARMACOKINETICS

IV:
Peak 30-45 min, duration 4 hr, half-life 64-68 min, excreted in urine

INTERACTIONS

 
Increase:
bleeding—anticoagulants

Increase:
methotrexate level—methotrexate, uric acid, bilirubicin, BUN, creatining, alk, phos, LDH

Increase:
ticarcillin concentrations—probenecid, sulfipyrazone

Decrease:
antimicrobial effect of ticarcillin—tetracyclines, aminoglycosides IV, chloramphenicol, macrolides, sulfonamides

Decrease:
effect—
oral contraceptives,
erythromycin

Drug/Lab Test

False positive:
urine glucose, urine protein, Coombs’ test

Increase:
LFTs, sodium, eosinophils, INR bleeding time

Decrease:
Hgb, potassium, platelets, WBC, granulocytes

NURSING CONSIDERATIONS
Assess:

• 
Infection: WBC, wound, temperature, sputum, urine, baseline and periodically

 
Pseudomembranous colitis:
diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC count, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given

 
Serious skin reactions:
Stevens-Johnson syndrome, toxic epidermal necrolysis; anaphylaxis: wheezing, rash, laryngeal edema; have emergency equipment nearby

• 
Hepatic studies: AST, ALT

• 
Blood studies: WBC, RBC, Hct, Hgb, bleeding time, platelets, baseline and periodically

• 
Renal studies: BUN, creatinine, sodium, potassium

• 
Bowel pattern before, during treatment

• 
Skin eruptions after administration of penicillin to 1 wk after discontinuing product

Perform/provide:

• 
EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment

• 
Storage of reconstituted sol 12-24 hr at room temp, or 3-7 days refrigerated

Evaluate:

• 
Therapeutic response: Resolution of infection

Teach patient/family:

• 
To report persistent diarrhea with blood, pus, mucous, or fever

• 
That culture may be taken after completed course of medication

• 
To report sore throat, fever, fatigue (may indicate superinfection); CNS effects (anxiety, depression, hallucinations, seizures)

• 
To wear or carry emergency ID if allergic to penicillins

• 
To use alternative birth control method instead of hormonal

TREATMENT OF OVERDOSE:

Withdraw product, maintain airway, administer EPINEPHrine, O
2
, IV corticosteroids for anaphylaxis

Other books

Lady of Sin by Madeline Hunter
Monster by Bernard L. DeLeo
Mourning Dove by Donna Simmons
Clover by R. A. Comunale
The Ghost Runner by Parker Bilal
Ana, la de Tejas Verdes by L. M. Montgomery
Boston Avant-Garde 4: Encore by Kaitlin Maitland